This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 22/8/1360    most recent 01.ATV.0000027102.53875.47v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sakakibara, M. Articles by Handa, S. Search for Related Content PubMed PubMed Citation Articles by Sakakibara, M. Articles by Handa, S. Pubmed/NCBI databases Substance via MeSH Related Collections Pacemaker Pulmonary biology and circulation Smooth muscle proliferation and differentiation Other anticoagulants

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1360.)
© 2002 American Heart Association, Inc.

Thrombosis

Application of Ex Vivo Flow Chamber System for Assessment of Stent Thrombosis

Mamoru Sakakibara^*; Shinya Goto^*; Koji Eto; Noriko Tamura; Takaaki Isshiki; Shunnosuke Handa

From the Division of Cardiology, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan, and the Department of Medicine (T.I.), Teikyo University School of Medicine, Tokyo, Japan.

Correspondence to Shinya Goto, MD, Division of Cardiology, Department of Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1153, Japan. E-mail shinichi{at}is.icc.u-tokai.ac.jp

Objective— Factors influencing platelet accumulation around stents were to be investigated by an ex vivo flow chamber system.

Methods and Results— Platelet accumulations on collagen surfaces under flow conditions were augmented in the presence of stents, especially at sites downstream from coil stents. Densitometric analysis revealed that 4.9±0.8 times more platelets accumulated downstream from coil stents than were formed downstream from tube stents (P<0.01), suggesting that stent morphology is an important determinant factor of its thrombogenicity. Platelet accumulations around stents were significantly inhibited by a combination of ticlopidine and aspirin, whereas aspirin alone produced only modest inhibition. Anti–glycoprotein IIb/IIIa (abciximab) inhibited platelet accumulation around stents in a dose-dependent manner, whereas the antibody blocking von Willebrand factor binding to glycoprotein Ib, which had been shown to inhibit platelet thrombus formation under high shear rates, did not inhibit the accumulation downstream from the coil stents. Our results suggest that the important characteristics of in vivo stent thrombosis, ie, augmented platelet accumulation with coil stents and the strong antithrombotic effect of the combination antiplatelet agents and an anti–glycoprotein IIb/IIIa, can be reproduced in ex vivo perfusion model.

Conclusions— We conclude that an ex vivo perfusion system is useful in the assessment of the thrombogenicity of various stents and in the screening of effective antiplatelet agents.

Key Words: stent thrombosis • platelets • glycoproteins • flow chamber • von Willebrand factor

This article has been cited by other articles:

				B. Aktas, M. Pozgajova, W. Bergmeier, S. Sunnarborg, S. Offermanns, D. Lee, D. D. Wagner, and B. Nieswandt Aspirin Induces Platelet Receptor Shedding via ADAM17 (TACE) J. Biol. Chem., December 2, 2005; 280(48): 39716 - 39722. [Abstract] [Full Text] [PDF]

				A. Hafezi-Moghadam, K. L. Thomas, and C. Cornelssen A novel mouse-driven ex vivo flow chamber for the study of leukocyte and platelet function Am J Physiol Cell Physiol, April 1, 2004; 286(4): C876 - C892. [Abstract] [Full Text] [PDF]